nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cladribine—PNP—osteoporosis	0.0162	1	CrCbGaD
Regadenoson—ADORA2A—Monoamine Transport—TNFRSF11B—osteoporosis	0.00148	0.0955	CbGpPWpGaD
Regadenoson—Urticaria—Alendronate—osteoporosis	0.00132	0.00137	CcSEcCtD
Regadenoson—Anxiety—Pamidronate—osteoporosis	0.00132	0.00136	CcSEcCtD
Regadenoson—Ill-defined disorder—Zoledronate—osteoporosis	0.00132	0.00136	CcSEcCtD
Regadenoson—Abdominal pain—Alendronate—osteoporosis	0.00132	0.00136	CcSEcCtD
Regadenoson—Shock—Risedronate—osteoporosis	0.00131	0.00136	CcSEcCtD
Regadenoson—Nervous system disorder—Risedronate—osteoporosis	0.00131	0.00135	CcSEcCtD
Regadenoson—Discomfort—Pamidronate—osteoporosis	0.00131	0.00135	CcSEcCtD
Regadenoson—Angioedema—Zoledronate—osteoporosis	0.0013	0.00134	CcSEcCtD
Regadenoson—Skin disorder—Risedronate—osteoporosis	0.0013	0.00134	CcSEcCtD
Regadenoson—Gastrointestinal pain—Calcitriol—osteoporosis	0.0013	0.00134	CcSEcCtD
Regadenoson—Abdominal pain—Raloxifene—osteoporosis	0.00129	0.00134	CcSEcCtD
Regadenoson—Vision blurred—Conjugated Estrogens—osteoporosis	0.00129	0.00133	CcSEcCtD
Regadenoson—Urticaria—Ibandronate—osteoporosis	0.00129	0.00133	CcSEcCtD
Regadenoson—Malaise—Zoledronate—osteoporosis	0.00128	0.00132	CcSEcCtD
Regadenoson—Abdominal pain—Ibandronate—osteoporosis	0.00128	0.00132	CcSEcCtD
Regadenoson—Syncope—Zoledronate—osteoporosis	0.00127	0.00132	CcSEcCtD
Regadenoson—Anaphylactic shock—Pamidronate—osteoporosis	0.00127	0.00131	CcSEcCtD
Regadenoson—Urticaria—Calcitriol—osteoporosis	0.00126	0.0013	CcSEcCtD
Regadenoson—Palpitations—Zoledronate—osteoporosis	0.00126	0.0013	CcSEcCtD
Regadenoson—Abdominal pain—Calcitriol—osteoporosis	0.00125	0.0013	CcSEcCtD
Regadenoson—Hypoaesthesia—Estradiol—osteoporosis	0.00125	0.00129	CcSEcCtD
Regadenoson—Angioedema—Conjugated Estrogens—osteoporosis	0.00125	0.00129	CcSEcCtD
Regadenoson—Shock—Pamidronate—osteoporosis	0.00125	0.00129	CcSEcCtD
Regadenoson—Loss of consciousness—Zoledronate—osteoporosis	0.00125	0.00129	CcSEcCtD
Regadenoson—Hypersensitivity—Estropipate—osteoporosis	0.00125	0.00129	CcSEcCtD
Regadenoson—Nervous system disorder—Pamidronate—osteoporosis	0.00125	0.00129	CcSEcCtD
Regadenoson—Vomiting—Etidronic acid—osteoporosis	0.00124	0.00128	CcSEcCtD
Regadenoson—Cough—Zoledronate—osteoporosis	0.00124	0.00128	CcSEcCtD
Regadenoson—Tachycardia—Pamidronate—osteoporosis	0.00124	0.00128	CcSEcCtD
Regadenoson—Connective tissue disorder—Estradiol—osteoporosis	0.00124	0.00128	CcSEcCtD
Regadenoson—Rash—Etidronic acid—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Convulsion—Zoledronate—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Dermatitis—Etidronic acid—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Hyperhidrosis—Pamidronate—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Syncope—Conjugated Estrogens—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Hypertension—Zoledronate—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Hypersensitivity—Alendronate—osteoporosis	0.00123	0.00127	CcSEcCtD
Regadenoson—Headache—Etidronic acid—osteoporosis	0.00122	0.00126	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00122	0.00126	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—ID4—osteoporosis	0.00122	0.0782	CbGpPWpGaD
Regadenoson—Asthenia—Estropipate—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Arthralgia—Zoledronate—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Myalgia—Zoledronate—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Chest pain—Zoledronate—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Palpitations—Conjugated Estrogens—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Insomnia—Risedronate—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Anxiety—Zoledronate—osteoporosis	0.00121	0.00125	CcSEcCtD
Regadenoson—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.0012	0.00124	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.0012	0.00124	CcSEcCtD
Regadenoson—Paraesthesia—Risedronate—osteoporosis	0.0012	0.00124	CcSEcCtD
Regadenoson—Discomfort—Zoledronate—osteoporosis	0.0012	0.00124	CcSEcCtD
Regadenoson—Asthenia—Alendronate—osteoporosis	0.00119	0.00123	CcSEcCtD
Regadenoson—Hypersensitivity—Ibandronate—osteoporosis	0.00119	0.00123	CcSEcCtD
Regadenoson—Cough—Conjugated Estrogens—osteoporosis	0.00119	0.00123	CcSEcCtD
Regadenoson—Dyspnoea—Risedronate—osteoporosis	0.00119	0.00123	CcSEcCtD
Regadenoson—Hypotension—Pamidronate—osteoporosis	0.00119	0.00123	CcSEcCtD
Regadenoson—Convulsion—Conjugated Estrogens—osteoporosis	0.00119	0.00122	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00118	0.00122	CcSEcCtD
Regadenoson—Eye disorder—Estradiol—osteoporosis	0.00118	0.00121	CcSEcCtD
Regadenoson—Tinnitus—Estradiol—osteoporosis	0.00117	0.00121	CcSEcCtD
Regadenoson—Hypersensitivity—Calcitriol—osteoporosis	0.00117	0.00121	CcSEcCtD
Regadenoson—Flushing—Estradiol—osteoporosis	0.00117	0.00121	CcSEcCtD
Regadenoson—Cardiac disorder—Estradiol—osteoporosis	0.00117	0.00121	CcSEcCtD
Regadenoson—Arthralgia—Conjugated Estrogens—osteoporosis	0.00117	0.0012	CcSEcCtD
Regadenoson—Chest pain—Conjugated Estrogens—osteoporosis	0.00117	0.0012	CcSEcCtD
Regadenoson—Myalgia—Conjugated Estrogens—osteoporosis	0.00117	0.0012	CcSEcCtD
Regadenoson—Asthenia—Ibandronate—osteoporosis	0.00116	0.0012	CcSEcCtD
Regadenoson—Anxiety—Conjugated Estrogens—osteoporosis	0.00116	0.0012	CcSEcCtD
Regadenoson—Nausea—Etidronic acid—osteoporosis	0.00116	0.0012	CcSEcCtD
Regadenoson—Anaphylactic shock—Zoledronate—osteoporosis	0.00116	0.0012	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00116	0.0012	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00116	0.0012	CcSEcCtD
Regadenoson—Diarrhoea—Estropipate—osteoporosis	0.00116	0.00119	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Risedronate—osteoporosis	0.00115	0.00119	CcSEcCtD
Regadenoson—Insomnia—Pamidronate—osteoporosis	0.00115	0.00119	CcSEcCtD
Regadenoson—Pain—Risedronate—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Angiopathy—Estradiol—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Shock—Zoledronate—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Paraesthesia—Pamidronate—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Diarrhoea—Alendronate—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Asthenia—Calcitriol—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Nervous system disorder—Zoledronate—osteoporosis	0.00114	0.00118	CcSEcCtD
Regadenoson—Immune system disorder—Estradiol—osteoporosis	0.00114	0.00117	CcSEcCtD
Regadenoson—Mediastinal disorder—Estradiol—osteoporosis	0.00113	0.00117	CcSEcCtD
Regadenoson—Dyspnoea—Pamidronate—osteoporosis	0.00113	0.00117	CcSEcCtD
Regadenoson—Tachycardia—Zoledronate—osteoporosis	0.00113	0.00117	CcSEcCtD
Regadenoson—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00113	0.00117	CcSEcCtD
Regadenoson—Somnolence—Pamidronate—osteoporosis	0.00113	0.00117	CcSEcCtD
Regadenoson—Skin disorder—Zoledronate—osteoporosis	0.00113	0.00116	CcSEcCtD
Regadenoson—Hyperhidrosis—Zoledronate—osteoporosis	0.00112	0.00116	CcSEcCtD
Regadenoson—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00112	0.00116	CcSEcCtD
Regadenoson—Diarrhoea—Raloxifene—osteoporosis	0.00112	0.00116	CcSEcCtD
Regadenoson—Dizziness—Estropipate—osteoporosis	0.00112	0.00115	CcSEcCtD
Regadenoson—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00112	0.00115	CcSEcCtD
Regadenoson—Diarrhoea—Ibandronate—osteoporosis	0.00111	0.00115	CcSEcCtD
Regadenoson—Mental disorder—Estradiol—osteoporosis	0.0011	0.00114	CcSEcCtD
Regadenoson—Dizziness—Alendronate—osteoporosis	0.0011	0.00114	CcSEcCtD
Regadenoson—Shock—Conjugated Estrogens—osteoporosis	0.0011	0.00114	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Pamidronate—osteoporosis	0.0011	0.00113	CcSEcCtD
Regadenoson—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.0011	0.00113	CcSEcCtD
Regadenoson—Erythema—Estradiol—osteoporosis	0.0011	0.00113	CcSEcCtD
Regadenoson—Gastrointestinal pain—Risedronate—osteoporosis	0.00109	0.00113	CcSEcCtD
Regadenoson—Tachycardia—Conjugated Estrogens—osteoporosis	0.00109	0.00113	CcSEcCtD
Regadenoson—Urticaria—Ethinyl Estradiol—osteoporosis	0.00109	0.00112	CcSEcCtD
Regadenoson—Pain—Pamidronate—osteoporosis	0.00109	0.00112	CcSEcCtD
Regadenoson—Diarrhoea—Calcitriol—osteoporosis	0.00109	0.00112	CcSEcCtD
Regadenoson—Skin disorder—Conjugated Estrogens—osteoporosis	0.00109	0.00112	CcSEcCtD
Regadenoson—Hypotension—Zoledronate—osteoporosis	0.00108	0.00112	CcSEcCtD
Regadenoson—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00108	0.00112	CcSEcCtD
Regadenoson—Dizziness—Raloxifene—osteoporosis	0.00108	0.00112	CcSEcCtD
Regadenoson—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00108	0.00112	CcSEcCtD
Regadenoson—Vomiting—Estropipate—osteoporosis	0.00107	0.00111	CcSEcCtD
Regadenoson—Dysgeusia—Estradiol—osteoporosis	0.00107	0.00111	CcSEcCtD
Regadenoson—Dizziness—Ibandronate—osteoporosis	0.00107	0.00111	CcSEcCtD
Regadenoson—Rash—Estropipate—osteoporosis	0.00107	0.0011	CcSEcCtD
Regadenoson—Dermatitis—Estropipate—osteoporosis	0.00107	0.0011	CcSEcCtD
Regadenoson—Urticaria—Risedronate—osteoporosis	0.00106	0.0011	CcSEcCtD
Regadenoson—Headache—Estropipate—osteoporosis	0.00106	0.00109	CcSEcCtD
Regadenoson—Vomiting—Alendronate—osteoporosis	0.00106	0.00109	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00106	0.00109	CcSEcCtD
Regadenoson—Abdominal pain—Risedronate—osteoporosis	0.00106	0.00109	CcSEcCtD
Regadenoson—Rash—Alendronate—osteoporosis	0.00105	0.00108	CcSEcCtD
Regadenoson—Insomnia—Zoledronate—osteoporosis	0.00105	0.00108	CcSEcCtD
Regadenoson—Dermatitis—Alendronate—osteoporosis	0.00105	0.00108	CcSEcCtD
Regadenoson—Feeling abnormal—Pamidronate—osteoporosis	0.00105	0.00108	CcSEcCtD
Regadenoson—Hypotension—Conjugated Estrogens—osteoporosis	0.00104	0.00108	CcSEcCtD
Regadenoson—Headache—Alendronate—osteoporosis	0.00104	0.00108	CcSEcCtD
Regadenoson—Paraesthesia—Zoledronate—osteoporosis	0.00104	0.00108	CcSEcCtD
Regadenoson—Vomiting—Raloxifene—osteoporosis	0.00104	0.00108	CcSEcCtD
Regadenoson—Gastrointestinal pain—Pamidronate—osteoporosis	0.00104	0.00107	CcSEcCtD
Regadenoson—Dyspnoea—Zoledronate—osteoporosis	0.00103	0.00107	CcSEcCtD
Regadenoson—Rash—Raloxifene—osteoporosis	0.00103	0.00107	CcSEcCtD
Regadenoson—Dermatitis—Raloxifene—osteoporosis	0.00103	0.00107	CcSEcCtD
Regadenoson—Somnolence—Zoledronate—osteoporosis	0.00103	0.00107	CcSEcCtD
Regadenoson—Vomiting—Ibandronate—osteoporosis	0.00103	0.00106	CcSEcCtD
Regadenoson—Tremor—Estradiol—osteoporosis	0.00103	0.00106	CcSEcCtD
Regadenoson—Headache—Raloxifene—osteoporosis	0.00103	0.00106	CcSEcCtD
Regadenoson—Rash—Ibandronate—osteoporosis	0.00102	0.00106	CcSEcCtD
Regadenoson—Dermatitis—Ibandronate—osteoporosis	0.00102	0.00105	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00102	0.00105	CcSEcCtD
Regadenoson—Ill-defined disorder—Estradiol—osteoporosis	0.00102	0.00105	CcSEcCtD
Regadenoson—Headache—Ibandronate—osteoporosis	0.00102	0.00105	CcSEcCtD
Regadenoson—Insomnia—Conjugated Estrogens—osteoporosis	0.00101	0.00104	CcSEcCtD
Regadenoson—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00101	0.00104	CcSEcCtD
Regadenoson—Vomiting—Calcitriol—osteoporosis	0.00101	0.00104	CcSEcCtD
Regadenoson—Nausea—Estropipate—osteoporosis	0.001	0.00104	CcSEcCtD
Regadenoson—Abdominal pain—Pamidronate—osteoporosis	0.001	0.00104	CcSEcCtD
Regadenoson—Paraesthesia—Conjugated Estrogens—osteoporosis	0.001	0.00104	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Zoledronate—osteoporosis	0.001	0.00103	CcSEcCtD
Regadenoson—Angioedema—Estradiol—osteoporosis	0.001	0.00103	CcSEcCtD
Regadenoson—Rash—Calcitriol—osteoporosis	0.001	0.00103	CcSEcCtD
Regadenoson—Dermatitis—Calcitriol—osteoporosis	0.001	0.00103	CcSEcCtD
Regadenoson—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000996	0.00103	CcSEcCtD
Regadenoson—Headache—Calcitriol—osteoporosis	0.000994	0.00103	CcSEcCtD
Regadenoson—Somnolence—Conjugated Estrogens—osteoporosis	0.000993	0.00103	CcSEcCtD
Regadenoson—Pain—Zoledronate—osteoporosis	0.000992	0.00102	CcSEcCtD
Regadenoson—Nausea—Alendronate—osteoporosis	0.000989	0.00102	CcSEcCtD
Regadenoson—Malaise—Estradiol—osteoporosis	0.000988	0.00102	CcSEcCtD
Regadenoson—Hypersensitivity—Risedronate—osteoporosis	0.000984	0.00102	CcSEcCtD
Regadenoson—Asthenia—Ethinyl Estradiol—osteoporosis	0.000983	0.00102	CcSEcCtD
Regadenoson—Syncope—Estradiol—osteoporosis	0.000982	0.00101	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—PTH1R—osteoporosis	0.000981	0.0631	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—CALCR—osteoporosis	0.000981	0.0631	CbGpPWpGaD
Regadenoson—Nausea—Raloxifene—osteoporosis	0.000973	0.001	CcSEcCtD
Regadenoson—Palpitations—Estradiol—osteoporosis	0.000968	0.001	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000964	0.000996	CcSEcCtD
Regadenoson—Nausea—Ibandronate—osteoporosis	0.000963	0.000995	CcSEcCtD
Regadenoson—Loss of consciousness—Estradiol—osteoporosis	0.000963	0.000994	CcSEcCtD
Regadenoson—Asthenia—Risedronate—osteoporosis	0.000959	0.00099	CcSEcCtD
Regadenoson—Feeling abnormal—Zoledronate—osteoporosis	0.000956	0.000987	CcSEcCtD
Regadenoson—Cough—Estradiol—osteoporosis	0.000956	0.000987	CcSEcCtD
Regadenoson—Pain—Conjugated Estrogens—osteoporosis	0.000955	0.000987	CcSEcCtD
Regadenoson—Gastrointestinal pain—Zoledronate—osteoporosis	0.000949	0.00098	CcSEcCtD
Regadenoson—Hypertension—Estradiol—osteoporosis	0.000946	0.000977	CcSEcCtD
Regadenoson—Nausea—Calcitriol—osteoporosis	0.000943	0.000974	CcSEcCtD
Regadenoson—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000938	0.000968	CcSEcCtD
Regadenoson—Hypersensitivity—Pamidronate—osteoporosis	0.000936	0.000967	CcSEcCtD
Regadenoson—Myalgia—Estradiol—osteoporosis	0.000933	0.000963	CcSEcCtD
Regadenoson—Arthralgia—Estradiol—osteoporosis	0.000933	0.000963	CcSEcCtD
Regadenoson—Chest pain—Estradiol—osteoporosis	0.000933	0.000963	CcSEcCtD
Regadenoson—Anxiety—Estradiol—osteoporosis	0.000929	0.00096	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000926	0.000957	CcSEcCtD
Regadenoson—Urticaria—Zoledronate—osteoporosis	0.000922	0.000952	CcSEcCtD
Regadenoson—Discomfort—Estradiol—osteoporosis	0.000922	0.000952	CcSEcCtD
Regadenoson—Abdominal pain—Zoledronate—osteoporosis	0.000917	0.000947	CcSEcCtD
Regadenoson—Diarrhoea—Risedronate—osteoporosis	0.000914	0.000944	CcSEcCtD
Regadenoson—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000914	0.000944	CcSEcCtD
Regadenoson—Asthenia—Pamidronate—osteoporosis	0.000911	0.000941	CcSEcCtD
Regadenoson—Dizziness—Ethinyl Estradiol—osteoporosis	0.000906	0.000936	CcSEcCtD
Regadenoson—Anaphylactic shock—Estradiol—osteoporosis	0.000894	0.000923	CcSEcCtD
Regadenoson—Urticaria—Conjugated Estrogens—osteoporosis	0.000887	0.000917	CcSEcCtD
Regadenoson—Dizziness—Risedronate—osteoporosis	0.000884	0.000913	CcSEcCtD
Regadenoson—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000883	0.000912	CcSEcCtD
Regadenoson—Shock—Estradiol—osteoporosis	0.00088	0.000909	CcSEcCtD
Regadenoson—Nervous system disorder—Estradiol—osteoporosis	0.000877	0.000906	CcSEcCtD
Regadenoson—Tachycardia—Estradiol—osteoporosis	0.000873	0.000901	CcSEcCtD
Regadenoson—Vomiting—Ethinyl Estradiol—osteoporosis	0.000871	0.0009	CcSEcCtD
Regadenoson—Diarrhoea—Pamidronate—osteoporosis	0.000869	0.000898	CcSEcCtD
Regadenoson—Skin disorder—Estradiol—osteoporosis	0.000868	0.000897	CcSEcCtD
Regadenoson—Hyperhidrosis—Estradiol—osteoporosis	0.000864	0.000893	CcSEcCtD
Regadenoson—Rash—Ethinyl Estradiol—osteoporosis	0.000864	0.000892	CcSEcCtD
Regadenoson—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000863	0.000892	CcSEcCtD
Regadenoson—Headache—Ethinyl Estradiol—osteoporosis	0.000859	0.000887	CcSEcCtD
Regadenoson—Hypersensitivity—Zoledronate—osteoporosis	0.000855	0.000883	CcSEcCtD
Regadenoson—Vomiting—Risedronate—osteoporosis	0.00085	0.000877	CcSEcCtD
Regadenoson—Rash—Risedronate—osteoporosis	0.000842	0.00087	CcSEcCtD
Regadenoson—Dermatitis—Risedronate—osteoporosis	0.000842	0.000869	CcSEcCtD
Regadenoson—Dizziness—Pamidronate—osteoporosis	0.00084	0.000868	CcSEcCtD
Regadenoson—Headache—Risedronate—osteoporosis	0.000837	0.000865	CcSEcCtD
Regadenoson—Asthenia—Zoledronate—osteoporosis	0.000832	0.00086	CcSEcCtD
Regadenoson—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000823	0.00085	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000815	0.000841	CcSEcCtD
Regadenoson—Nausea—Ethinyl Estradiol—osteoporosis	0.000814	0.000841	CcSEcCtD
Regadenoson—Insomnia—Estradiol—osteoporosis	0.000809	0.000835	CcSEcCtD
Regadenoson—Vomiting—Pamidronate—osteoporosis	0.000808	0.000834	CcSEcCtD
Regadenoson—Paraesthesia—Estradiol—osteoporosis	0.000803	0.000829	CcSEcCtD
Regadenoson—Asthenia—Conjugated Estrogens—osteoporosis	0.000802	0.000828	CcSEcCtD
Regadenoson—Rash—Pamidronate—osteoporosis	0.000801	0.000827	CcSEcCtD
Regadenoson—Dermatitis—Pamidronate—osteoporosis	0.0008	0.000826	CcSEcCtD
Regadenoson—Dyspnoea—Estradiol—osteoporosis	0.000797	0.000823	CcSEcCtD
Regadenoson—Headache—Pamidronate—osteoporosis	0.000796	0.000822	CcSEcCtD
Regadenoson—Somnolence—Estradiol—osteoporosis	0.000795	0.000821	CcSEcCtD
Regadenoson—Diarrhoea—Zoledronate—osteoporosis	0.000794	0.00082	CcSEcCtD
Regadenoson—Nausea—Risedronate—osteoporosis	0.000794	0.00082	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Estradiol—osteoporosis	0.000772	0.000797	CcSEcCtD
Regadenoson—Dizziness—Zoledronate—osteoporosis	0.000767	0.000792	CcSEcCtD
Regadenoson—Pain—Estradiol—osteoporosis	0.000765	0.00079	CcSEcCtD
Regadenoson—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000764	0.000789	CcSEcCtD
Regadenoson—Nausea—Pamidronate—osteoporosis	0.000754	0.000779	CcSEcCtD
Regadenoson—Dizziness—Conjugated Estrogens—osteoporosis	0.000739	0.000763	CcSEcCtD
Regadenoson—Vomiting—Zoledronate—osteoporosis	0.000738	0.000762	CcSEcCtD
Regadenoson—Feeling abnormal—Estradiol—osteoporosis	0.000737	0.000761	CcSEcCtD
Regadenoson—Rash—Zoledronate—osteoporosis	0.000732	0.000756	CcSEcCtD
Regadenoson—Gastrointestinal pain—Estradiol—osteoporosis	0.000731	0.000755	CcSEcCtD
Regadenoson—Dermatitis—Zoledronate—osteoporosis	0.000731	0.000755	CcSEcCtD
Regadenoson—Headache—Zoledronate—osteoporosis	0.000727	0.000751	CcSEcCtD
Regadenoson—Vomiting—Conjugated Estrogens—osteoporosis	0.00071	0.000734	CcSEcCtD
Regadenoson—Urticaria—Estradiol—osteoporosis	0.00071	0.000734	CcSEcCtD
Regadenoson—Abdominal pain—Estradiol—osteoporosis	0.000707	0.00073	CcSEcCtD
Regadenoson—Rash—Conjugated Estrogens—osteoporosis	0.000704	0.000728	CcSEcCtD
Regadenoson—Dermatitis—Conjugated Estrogens—osteoporosis	0.000704	0.000727	CcSEcCtD
Regadenoson—Headache—Conjugated Estrogens—osteoporosis	0.0007	0.000723	CcSEcCtD
Regadenoson—Nausea—Zoledronate—osteoporosis	0.000689	0.000712	CcSEcCtD
Regadenoson—Nausea—Conjugated Estrogens—osteoporosis	0.000664	0.000685	CcSEcCtD
Regadenoson—Hypersensitivity—Estradiol—osteoporosis	0.000659	0.00068	CcSEcCtD
Regadenoson—Asthenia—Estradiol—osteoporosis	0.000641	0.000663	CcSEcCtD
Regadenoson—Diarrhoea—Estradiol—osteoporosis	0.000612	0.000632	CcSEcCtD
Regadenoson—Dizziness—Estradiol—osteoporosis	0.000591	0.000611	CcSEcCtD
Regadenoson—Vomiting—Estradiol—osteoporosis	0.000568	0.000587	CcSEcCtD
Regadenoson—Rash—Estradiol—osteoporosis	0.000564	0.000582	CcSEcCtD
Regadenoson—Dermatitis—Estradiol—osteoporosis	0.000563	0.000582	CcSEcCtD
Regadenoson—Headache—Estradiol—osteoporosis	0.00056	0.000579	CcSEcCtD
Regadenoson—Nausea—Estradiol—osteoporosis	0.000531	0.000549	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—PTH—osteoporosis	0.000516	0.0331	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—IL1B—osteoporosis	0.000432	0.0277	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—PTHLH—osteoporosis	0.000427	0.0275	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—CALCA—osteoporosis	0.000376	0.0242	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CALCR—osteoporosis	0.000356	0.0229	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—PTH1R—osteoporosis	0.000356	0.0229	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAP1A—osteoporosis	0.000338	0.0217	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—TNF—osteoporosis	0.000313	0.0201	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.00028	0.018	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADCY5—osteoporosis	0.000268	0.0172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RAP1A—osteoporosis	0.00026	0.0167	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00024	0.0154	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KL—osteoporosis	0.000228	0.0146	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CALCR—osteoporosis	0.000201	0.0129	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTH1R—osteoporosis	0.000201	0.0129	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—POMC—osteoporosis	0.000197	0.0127	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—PTH—osteoporosis	0.000187	0.012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CALCR—osteoporosis	0.000183	0.0118	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTH1R—osteoporosis	0.000183	0.0118	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CNR2—osteoporosis	0.000182	0.0117	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ADCY5—osteoporosis	0.000178	0.0115	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KL—osteoporosis	0.000175	0.0113	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—WNT1—osteoporosis	0.000171	0.011	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—MGLL—osteoporosis	0.00016	0.0103	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS2—osteoporosis	0.000156	0.01	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—LEP—osteoporosis	0.000156	0.01	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—PTHLH—osteoporosis	0.000155	0.00997	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MGLL—osteoporosis	0.000145	0.00934	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ADCY5—osteoporosis	0.000137	0.00881	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CALCA—osteoporosis	0.000137	0.00878	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS1—osteoporosis	0.000136	0.00875	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6R—osteoporosis	0.000128	0.00822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS2—osteoporosis	0.00012	0.00771	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SOST—osteoporosis	0.000119	0.00768	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CALCR—osteoporosis	0.000108	0.00694	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTH1R—osteoporosis	0.000108	0.00694	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTH—osteoporosis	0.000106	0.0068	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS1—osteoporosis	0.000105	0.00673	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR2—osteoporosis	0.000103	0.00663	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6R—osteoporosis	9.84e-05	0.00632	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTH—osteoporosis	9.6e-05	0.00618	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	9.38e-05	0.00603	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CNR2—osteoporosis	9.36e-05	0.00602	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—WNT1—osteoporosis	8.8e-05	0.00566	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTHLH—osteoporosis	8.76e-05	0.00564	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MGLL—osteoporosis	8.58e-05	0.00552	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LRP5—osteoporosis	8.37e-05	0.00538	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LRP6—osteoporosis	8.01e-05	0.00515	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTHLH—osteoporosis	7.96e-05	0.00512	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CALCA—osteoporosis	7.72e-05	0.00496	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—osteoporosis	7.14e-05	0.00459	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CALCA—osteoporosis	7.01e-05	0.00451	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TLN1—osteoporosis	6.76e-05	0.00435	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—P4HB—osteoporosis	5.83e-05	0.00375	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—osteoporosis	5.81e-05	0.00374	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	5.7e-05	0.00366	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTH—osteoporosis	5.67e-05	0.00365	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAP1A—osteoporosis	5.58e-05	0.00359	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CNR2—osteoporosis	5.53e-05	0.00356	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADCY5—osteoporosis	5.49e-05	0.00353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NFATC1—osteoporosis	5.44e-05	0.0035	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DKK1—osteoporosis	5.4e-05	0.00347	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WNT1—osteoporosis	5.2e-05	0.00334	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGA—osteoporosis	5.06e-05	0.00325	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADCY5—osteoporosis	4.98e-05	0.0032	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTHLH—osteoporosis	4.7e-05	0.00302	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BMP2—osteoporosis	4.7e-05	0.00302	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGB—osteoporosis	4.6e-05	0.00296	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PSMA2—osteoporosis	4.44e-05	0.00286	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PSMA5—osteoporosis	4.44e-05	0.00286	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—osteoporosis	4.38e-05	0.00282	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CALCA—osteoporosis	4.14e-05	0.00266	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—osteoporosis	4.04e-05	0.0026	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KL—osteoporosis	3.76e-05	0.00242	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—osteoporosis	3.67e-05	0.00236	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6R—osteoporosis	3.58e-05	0.0023	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADCY5—osteoporosis	2.94e-05	0.00189	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPP1—osteoporosis	2.85e-05	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS2—osteoporosis	2.58e-05	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—osteoporosis	2.52e-05	0.00162	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ESR1—osteoporosis	2.41e-05	0.00155	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS1—osteoporosis	2.25e-05	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—osteoporosis	2.17e-05	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6R—osteoporosis	2.11e-05	0.00136	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—osteoporosis	2.08e-05	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—osteoporosis	1.59e-05	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—osteoporosis	1.25e-05	0.000805	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—osteoporosis	1.25e-05	0.000803	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—osteoporosis	9.41e-06	0.000605	CbGpPWpGaD
